StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Nurtec ODT / Vydura (rimegepant by Quarter

Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — U.S. revenues ($M) ($M)

QuarterlyAnnual

Pfizer Nurtec ODT / Vydura (rimegepant: $365M in Q2 2026, up 9.6% from a year earlier.

Latest, Q2 2026
365
Period ended Jun 28, 2026
Change on a year earlier
+9.6%
333 in Q2 2025
History
15 quarters
Since Q4 2022
Sources
11
Documents cited below

Where the Q2 2026 figure comes from

“|| Nurtec ODT/Vydura | 421 | 359 | 18% | 17% | 365 | 333 | 10% | 56 | 25 | * | *”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — U.S. revenues ($M) ($M)Year on yearSource
Q2 2026Jun 28, 2026365+9.6%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 2026312+36.8%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 2025377+1.1%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 2025383+22.0%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 2025333-1.8%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2025Mar 30, 2025228+36.5%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2024Dec 31, 2024373+35.6%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2024Sep 29, 2024314+38.3%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 2024339+38.9%Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 2024167+2.5%Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 2023275+30.3%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2023Oct 1, 2023227–Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2023Jul 2, 2023244–Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2023Apr 2, 2023163–Form 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗
Q4 2022Dec 31, 2022211–Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗

Breakdown

What makes up nurtec ODT / Vydura (rimegepant

Cite this data

StockData. (2026). Pfizer Nurtec ODT / Vydura (rimegepant ($M), quarterly Q4 2022–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/nurtec-us

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.